Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Inclusion Criteria: Patients must have high-sensitivity troponin or CKMB above the upper limit of normal with at least one of the following criteria: 1. Anginal symptoms suggestive of cardiac ischemia 1. Accelerating pattern of anginal pain (episodes of angina that have at least 5 minutes duration and are more frequent, severe, longer in duration and/or precipitated by less exertion). 2. Prolonged (\>20 minutes) or recurrent anginal pain at rest or with minimal effort. 3. Anginal pain at rest or with minimal exertion, and at least 20 minutes of duration, occurring \>48 hours after an acute Q-wave myocardial infarction. 2. ECG criteria 1. New, persistent or transient ST-segment depression \>0,1 mV (0,08 seconds after the J-point) in at least 2 extremity leads or 3 precordial leads. 2. New, persistent or transient ST-segment elevation in two contiguous leads ≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3, and/or ≥0.1 mV in other leads. Patients will be enrolled within 96 hours of coronary angiography Exclusion Criteria: * Contraindication for hydroxychloroquine (porphyria, psoriasis, retinopathy, hypersensitivity) * Rheumatoid arthritis or other rheumatic disease * Significant neuropathy of any cause * Cardiomyopathy (diagnosed before the onset of index hospitalization) * Muscle disease (that could worsen by the use of hydroxychloroquine) * Pregnant or nursing women, and women of childbearing potential without efficient contraceptives. * Angina precipitated by obvious provoking factors * Prolonged ECG's corrected QT interval (\>480 ms) * Ongoing antibiotic therapy of any duration * Uncontrolled severe cardiac arrhythmia resulting in hemodynamic instability * Severe hepatic failure (alanine transaminase or gamma-glutamyltransferase ≥2 times above normal limits or international normalized ratio (INR) \>1,5 and patient not using warfarin, and due to other than cardiac reasons). * Renal failure, glomerular filtration rate \<50 ml/min/1,73m2 * Hemoglobin \<100 g/l (if not possible to correct with transfusion) * Planned percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) * Index myocardial infarction due to PCI or CABG restenosis. * Inability to interpret ST-T segment changes on ECG (e.g. complete left bundle branch block or paced rhythm) * Prior thrombolytic therapy (within 12 hours) * Inability to give informed consent * Fulminant vomiting or other disability to give oral medication * Over 80 years of age * Life expectancy less than one year * Receiving another investigational drug within 4 weeks prior to the study. (Patients who have participated in investigational trials before the 4-week time period may be randomized as long as they have reached the primary endpoint). * Patients with any other medical condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient In addition, patients are not eligible for the PET/CT subgroup if they have received statin-therapy in the last 2 months prior to the hospitalization (i.e. statin therapy started during the index hospitalization is not an exclusion criteria).